May 29, 2017 11:51 PM ET

Pharmaceuticals

Company Overview of Intra-Cellular Therapies, Inc.

Company Overview

Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson’s and Alzheimer’s disease. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease. The company is ...

430 East 29th Street

Suite 900

New York, NY 10016

United States

41 Employees

Phone:

646-440-9333

Fax:

646-440-9334

Key Executives for Intra-Cellular Therapies, Inc.

Co-Founder, Chairman, Chief Executive Officer and President
Age: 63
Total Annual Compensation: $1.1M
Chief Financial Officer, Vice President of Finance, Treasurer and Assistant Secretary
Age: 60
Total Annual Compensation: $560.0K
Senior Vice President, General Counsel, Corporate Compliance Officer and Secretary
Age: 43
Total Annual Compensation: $618.8K
Chief Scientific Officer and Senior Vice President
Age: 65
Total Annual Compensation: $560.0K
Senior Vice President of Clinical Development
Age: 50
Total Annual Compensation: $525.0K
Compensation as of Fiscal Year 2016.

Intra-Cellular Therapies, Inc. Key Developments

Khang & Khang LLP Announces Securities Class Action Lawsuit Against Intra-Cellular Therapies, Inc

Khang & Khang LLP announced the filing of a class action lawsuit against Intra-Cellular Therapies, Inc. Investors who purchased or otherwise acquired shares between August 12, 2014 and April 28, 2017, inclusive (the class Period), are encouraged to contact the Firm in advance of the July 11, 2017 lead plaintiff motion deadline. According to the Complaint, throughout the Class Period, Intra-Cellular made false and/or misleading statements and/or failed to disclose: that findings related to toxicity in animals treated with lumateperone (ITI-007) were observed; that these findings posed an additional safety concern regarding lumateperone; and that as a result of the above, the Company's public statements were materially false and misleading at all relevant times. On August 4, 2016, the Company's CEO Sharon Mates touted the efficacy and safety of ITI-007 for the treatment of schizophrenia. On May 1, 2017, Intra-Cellular disclosed that the U.S. Food and Drug Administration requested information from the Company in order to verify whether or not there are safety risks associated with long term exposure of ITI-007 to patients. Upon release of this news, Intra-Cellular's stock price fell materially, which harmed investors according to the Complaint.

Rosen Law Firm Continues to Investigate Securities Claims against Intra-Cellular Therapies, Inc

Rosen Law Firm announced it is continuing to investigate potential securities claims on behalf of shareholders of Intra-Cellular Therapies, Inc. resulting from allegations that Intra-Cellular Therapies may have issued materially misleading business information to the investing public. Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Intra-Cellular Therapies investors.

Intra-Cellular Therapies, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2017

Intra-Cellular Therapies, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2017. For the quarter, loss from operations was $27,754,157,000 compared to $28,497,853,000 a year ago. Net loss was $26,933,582,000 or $0.62 per basic and diluted share compared to $27,841,449,000 or $0.64 per basic and diluted share a year ago.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Intra-Cellular Therapies, Inc., please visit www.intracellulartherapies.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.